APOA5 and metabolic dysfunction-associated steatotic liver disease: Similarly, our study demonstrated that obese mice with NAFLD had higher hepatic apoA5 expression and TG level, and metformin treatment resulted in a considerable reduction of both hepatic apoA5 expression and TG level in livers of these animals.